35 results about "Obstructive emphysema" patented technology

The invention relates to a Chinese medicament for treating chronic obstructive emphysema and pulmonary heart disease, which comprises the following crude herbal materials (by weight portion): chastetree fruit 15-25 parts, apricot kernel 5-15 parts, pinellia tuber 12-20 parts, schisandra fruit 10-35 parts, Sichuan fritillary bulb 8-35 parts, rhizome of Sichuan lovage 12-20 parts, red sage root 15-30 parts, root of balloonflower 5-15 parts, mulberry bark 8-30 parts, coltsfoot flower 10-18 parts, astragalus root 15-30 parts, pilose asiabell root 10-40 parts, ginkgo nut 12-20 parts, trichosanthes anguina 20-35 parts, white atractylodes rhizome 10-20 parts, Chinese angelica root 15-35 parts, poria cocos wolf 10-30 parts, honeysuckle flower 10-30 parts, coptis root 5-15 parts, golden buckwheat rhizome 10-30 parts, ledebouriella root 9-30 parts, licorice root 5-20 parts, dried peach 12-30 parts, wild or spiny jujuba seed 10-30 parts, pearl 6-15 parts.

The invention discloses a kind of baicalein derivatives and a preparation method and application thereof. Pharmacological tests prove that the compounds have the obvious function of dilating bronchi and can be used to prepare the medicines used for preventing or curing chronic obstructive emphysema caused by bronchial constriction.

The invention relates to a Chinese traditional medicinal composition for treating chronic obstructive emphysema and preparation method, wherein the composition mainly comprises the extract of astragalus root, morinda root, peach kernels, leeches, ardisia japonica, epimeddium, psoralea fruit, root of red rooted saliva, epimeddium.

The invention relates to novel pharmacological action of traditional Chinese medicine salvianolic acid A and application thereof in the preparation of products for preventing, relieving and/or treating pulmonary arterial hypertension and its complications. The salvianolic acid A has the advantages that the salvianolic acid A has the pharmacological action of relieving pulmonary circulation pressure rise, the pharmacological actions of relieving right heart failure due to pulmonary arterial hypertension, improving right ventricular hypertrophy and right ventricular enlargement, improving heart injury due to pulmonary arterial hypertension, and restoring from heart failure, and the pharmacological actions of lowering endothelin-1 level in pulmonary tissues, relieving pulmonary arterial remodeling and improving pathologic damage of pulmonary tissues; the salvianolic acid A is a monomer compound extracted from Salvia miltiorrhiza, has low toxicity, has a wide source range of material, has promising application and development prospect, is an ideal novel traditional Chinese medicine monomer for treating pulmonary arterial hypertension and its complications, and may be applied to prepare products for preventing, relieving and treating pulmonary arterial hypertension and its complications, such as chronic obstructive pulmonary emphysema, chronic pulmonary heart disease and heart failure.

The invention discloses a traditional Chinese medicine composition for treating phlegm-heat lung-stagnation type obstructive emphysema and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw material medicines: thunberg fritillary bulb, caulis bambusae in taeniam, tabasheer, Platycodon grandiflorum, fructus perillae, the tuber of stemona, birthwort, flos farfarae, the root bark of white mulberry, Japanese Ardisia Herb, folium rhododendri daurici, Momordica grosvenori, rhizoma anemarrhenae, dayflower, Scutellaria baicalensis, Meadowrue Root and Rhizome, common andrographis Herb, Houttuynia cordata, lily, asparagus fern, Changium smyrnioides and rhizoma polygonati. The traditional Chinese medicine composition has the effects of clearing away the lung-heat and dissipating heat and calming the adverse-rising energy and relieving asthma and is mainly used for treating chronic phlegm-heat lung-stagnation symptoms of obstructive emphysema. By utilizing the theory of traditional Chinese medicine, the traditional Chinese medicine composition has the effects of regulating the disease resistance of the whole body, improving lung and bronchus tissue blood metabolism, enhancing the gas exchange efficiency, emphasizing on treatment based on syndrome differentiation in a targeted therapy manner, improving the diaphragm breath degree, promoting phlegm elimination, improving the respiratory muscle functions, keeping unobstructed airway and resisting infection.

The invention discloses a medicine composition used for treating lung and kidney qi deficiency type chronic obstructive emphysema and a preparation method thereof. Raw medicine materials of the medicine composition comprise, astragalus, convolvulate asiabell roots, amomum, Chinese yam, mica, cordyceps liangshanensis, walnut kernels, agilawood, fructus psoraleae, fructus schizandrae, ginkgo, semen ziziphi spinosae, nutgall, polygonum cynanchoides hemsl, caulis bambusae in taeniis, caudate sweetleaf flowers, artemisia vestita, herbs of little platanthera, cerealose, white fungi and jujubes. The medicine composition has the advantages that the medicine composition is mainly used for nourishing the kidney and lung and preventing asthma and assists in astringing the lung to stop cough and regulating qi-flowing for eliminating phlegm, treats the lung and kidney qi deficiency type chronic obstructive emphysema, and has the advantages of being quick in working, accurate in treatment effect, high in safety, free of toxic function and not prone to reappearing.

The invention discloses a medicine for treating phlegm clouding clear orifices obstructive emphysema, which comprises the following active ingredients: rhizoma phragmitis, rhizoma decumbentis, cordate houttuynia, Indian iphigenia bulb, folium sennae, aloe, lilac daphne flower bud, semen persicae, ganoderma lucidum, polygala tenuifolia, rhizoma acori graminei, tussilago, folium eriobotryae, semen lepidii, folium rhododendri daurici, momordica grosvenori, gleditsia sinensis, inula flower, concretio silicea bambusae, seaweed, fritillaria cirrhosa, snakegourd fruit, bamboo juice, sea clam shells, chlorite schist, platycodon grandiflorum, boat-fruited sterculia seeds, pummelo peel and semen pharbitidis. The medicine has an effect of removing phlegm to enlighten and mainly treats the phlegm clouding clear orifices obstructive emphysema. The medicine employs the traditional Chinese medicine theory, improves overall immunity of an organism and pathogenic evil resistance, reduces complications, increases a cure rate, reduces a recurrence rate, is wide in medicine resource, has smaller toxic and side effects and low possibility of medicine tolerance, is convenient to administer, is easily accepted by a patient, can alleviate mental stress of a patient obviously, improves life quality of the patient and can be used for clinical market popularization.

The invention relates to a novel pharmacologic effect of a novel Rho kinase inhibitor (DL0805 derivative) with indazole as a mother nucleus, and an application of the compound in preparation of a product for preventing, alleviating and/or treating PAH and complications thereof. The DL0805 derivative has the pharmacologic effects of relaxing pulmonary artery vessels, reducing pulmonary artery pressure, treating pulmonary vascular injury caused by the PAH, recovering lung tissue functions, relieving hypertrophy and enlargement of right ventricle, treating cardiac failure and liver function damages, significantly reducing death rate of animals suffered from the PAH, and preventing and treating the PAH and complications thereof. The DL0805 derivative can be synthesized through known methods and has mature preparation processes, so that a reliable source of the compound can be provided. The compound is excellent for treating the PAH and complications thereof and can be used for preparing the product for preventing, alleviating and/or treating the PAH and the complications thereof, such as chronic obstructive emphysema, chronic pulmonary heart diseases, right heart failure, liver function damages.

The invention relates to application of compound puerarin in the preparation of drugs for preventing, relieving and/or treating pulmonary arterial hypertension and complications thereof. A large amount of clinical practice shows that the puerarin is good in curative effect on the pulmonary arterial hypertension and is an ideal compound for treating the pulmonary arterial hypertension and the complications thereof, and the puerarin can be used for preparing products for preventing, relieving and/or treating lung injury diseases caused by the pulmonary arterial hypertension, chronic pneumonia and exogenous materials and unexplained pulmonary arterial pressure increasing and complications thereof such as chronic obstructive emphysema, chronic pulmonary heart disease and cardiac failure.

The invention discloses traditional Chinese composition for treating qi deficiency and blood stasis phlegm-dampness stagnation type obstructive emphysema. The traditional Chinese composition is prepared by astragalus membranaceus, Chinese yam, radix rehmanniae preparata, donkey-hide gelatin, codonopsis pilosula, rhizoma zingiberis, cortex cinnamomi, English walnut seeds, schisandra chinensis, salviae miltiorrhizae, adenophora stricta, lapis chlorite, fluorite, angelica sinensis, ligusticum wallichii, radix scrophulariae, bulbus fritillariae cirrhosae, belamcanda chinensis, roasted folium eriobotryae, asparagus cochinchinensis, magnolia officinalis, pinellia ternate, dried tangerine or orange peel, exocarpium citri rubrum, fatsia japonica, lumbricus, perillaseed, sinapis alba, scutellaria baicalensis, cordate houttuynia, ixeris japonica, honeysuckle, Hei xi pills, cortex mori radicis, poria cocos peel, snakegourd seeds, perilla leaves, cabbage mustard, periostracum cicada, radish seeds, leaves of common dysosma, dodder, ephedra, gypsum, almonds, peach kernels, os balanophylliae stalactium tubuliforme, pepperweed seeds, semen plantaginis, rohdea japonica, tea plant roots, fresh bamboo juice and liquorice. It is tested by clinical trials that the traditional Chinese composition is capable of treating the qi deficiency and blood stasis phlegm-dampness stagnation type obstructive emphysema safely and effectively.

The invention relates to a drug for treating chronic obstructive emphysema. The drug is prepared from, by weight, 10 parts of cortex lycii radicis, 15 parts of rhizoma atractylodis macrocephalae, 9 parts of rhizoma pinelliae, 10 parts of fewflower lysionotus herbs, 12 parts of herba ephedrae, 10 parts of herba pteridis multifidae, 15 parts of bulbus fritillariae ussuriensis, 9 parts of selfheal and 8 parts of fructus perillae. According to the drug, cortex lycii radicis can clear the lung to decrease internal fire; rhizoma atractylodis macrocephalae can strengthen the spleen, benefit Qi, eliminate dampness and promote urination; rhizoma pinelliae can eliminate dampness and dissipate phlegm; fewflower lysionotus herbs can clear heat and remove dampness; herba ephedrae can ventilate the lung, relieve asthma, promote urination and eliminate swelling; herba pteridis multifidae can clear heat and remove dampness; bulbus fritillariae ussuriensis can clear heat, moisten the lung, dissipate phlegm and relieve a cough; selheal can clear fire and remove stasis; fructus perillae can depress Qi and dissolve phlegm. All the traditional Chinese medicines are combined to jointly achieve the effects of nourishing Yin, moistening the lung, nourishing the spleen and strengthening the kidney to effectively treat the chronic obstructive emphysema. Clinical experiments prove that the drug can safely and effectively treat the chronic obstructive emphysema.

The invention belongs to the technical field of traditional Chinese medicines and relates to an agent for treating obstructive emphysema. The agent for treating obstructive emphysema is prepared fromthe following components in parts by weight: 13-16 parts of Chinese yam, 18-22 parts of gorgon fruit, 17-21 parts of ginkgo, 10-20 parts of bighead atractylodes rhizome, 10-25 parts of poria cocos, 9-15 parts of liquorice, 5-10 parts of astragalus, 12-15 parts of perillaseed, 10-20 parts of burdock, 5-20 parts of semen raphani, 3-9 parts of pepper and 10-30 parts of borneol. The agent for treatingobstructive emphysema, disclosed by the invention, is low in price and exact in curative effect, and due to reasonable compatibility of various components in medicinal composition and adjuvant and mutual supplement and coordination of effects, the agent has the advantages of being short in course of treatment, fast in efficacy, excellent in curative effects and the like, is a pure natural raw drug having compatibility, does not produce any side effects, dependence or drug resistance, and is widely applicable to prevention, control and treatment of pulmonary emphysema caused by various pathogens.

The invention relates to a medicine for treating chronic obstructive emphysema and in particular relates to a traditional Chinese medicine composition which is prepared by using Chinese herbal medicines as raw materials and is used for treating chronic obstructive emphysema. The traditional Chinese medicine composition is characterized by comprising the following active pharmaceutical ingredients by weight: 10-20g of ginkgo leaves, 15-25g of safflower, 3-7g of Chinese angelica, 6-8g of liquorice, 3-5g of Sichuan lovage rhizome, 10-20g of Indian bread and 10-20g of salvia miltiorrhiza. According to the dialectic theory of the traditional Chinese medicine, the traditional Chinese medicine composition has simple components, is accessible in materials and low in cost, has good curative effects, does not have any toxic or side effect, has the obvious functions of relieving cough and reducing sputum and relieving asthma, has obvious functions of resisting bacteria and diminishing inflammation, achieving spasmolysis and relieving asthma, improving the pulmonary ventilation function and reducing pulmonary artery pressure for patients with chronic obstructive pulmonary diseases, and can be used for effectively treating chronic obstructive emphysema.

The invention discloses traditional Chinese medicine for treating bronchitic obstructive emphysema and a preparation method thereof. The traditional Chinese medicine is composed of, by weight, 30-40 parts of houttuynia cordata, 30-40 parts of rhizoma atractylodes, 30-40 parts of astragalus, 30-40 parts of Chinese yam, 30-40 parts of fructus corni, 30-40 parts of prepared rehmannia root, 30-40 parts of radix ophiopogonis, 20-30 parts of flos farfarae, 20-30 parts of aster, 20-30 parts of perillaseed, 20-30 parts of radish seed, 15-20 parts of field pennycress, 10-20 parts of semen brassicae, 10-20 parts of red ginseng, 10-20 parts of scutellaria baicalensis, 10-15 parts of semen cannabis, 10-15 parts of gelatin bead, 10-15 parts of monkshood, 10-15 parts of cinnamon, 10-15 parts of ligusticum wallichii, 10-15 parts of eaglewood, 10-15 parts of prepared rhizoma pinellia with juice of ginger, 3-5 jujube and 2-5 parts of honey-fried herba ephedrae. Pure Chinese herbs are adopted, so that the traditional Chinese medicine is free of side effect, high in healing rate, good in effect and leas prone to recurrence, and the preparation method is simple.

The invention discloses a traditional Chinese medicine preparation for treating chronic obstructive emphysema due to insufficiency of QI of the lung and the kidney, and belongs to the technical field of traditional Chinese medicine. The inventor of the traditional Chinese medicine preparation aims at the pathogenesis of the insufficiency of QI of the lung and the kidney; according to the theory of diagnosis and treatment based on the overall analysis of the illness and the patient's condition, the traditional Chinese medicine of ivory-white chirita herb, thesium chinense, laxflower embelia roots, fomes oficinalis sporophore, crinite uraria roots, tibet goldenray roots and boxleaf atalantia roots is selected to be prepared into traditional Chinese medicine decoction; through clinic tests, the total effectiveness rate reaches 100 percent. Particularly, the traditional Chinese medicine also has a better curative effect on night sweat.